1

- A novel method for predicting Lp(a) levels from
- ² routine outpatient genomic testing identifies those at
- ³ risk of cardiovascular disease across a diverse

4 cohort

- 5 Natalie Telis^{*1}, Hang Dai^{*1}, Ashley Waring², David Kann³, Dana Wyman¹, Simon White¹, Basil
- 6 Khuder¹, Francisco Tanudjaja¹, Alexandre Bolze¹, Matthew E. Levy¹, Cassie Hajek¹, Lisa M.
- 7 McEwen¹, Douglas Stoller³, Christopher N. Chapman⁴, C. Anwar A. Chahal⁵, Daniel P. Judge²,
- 8 Douglas A. Olson⁶, Joseph J. Grzymski^{7,8}, Nicole L. Washington¹, William Lee¹, Elizabeth T.
- 9 Cirulli¹, Shishi Luo¹, Kelly Schiabor Barrett¹
- 10
- ¹Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401
- ²Division of Cardiology, Medical University of South Carolina, 30 Courtenay Drive, MSC 592, Charleston,
- 13 SC 29425
- ³Center for Inherited Cardiovascular Diseases, WellSpan Health, 157 North Reading Road, Ephrata,
 Pennsylvania 17522
- 16 ⁴University of Nebraska Medical Center, Omaha, Nebraska, USA
- 17 ⁵Department of Pathology & Laboratory Medicine; St. Luke's University Health Network; Bethlehem PA
- ⁶HealthPartners, Minneapolis, MN 55125
- ⁷University of Nevada, School of Medicine; 1664 N. Virginia Reno, Nevada 89557
- 20 ⁸Renown Health, Reno, Nevada 89521
- 21 Abstract

22

23 **Background**: Lipoprotein(a) (Lp(a)) levels are a largely genetically determined and often an 24 unmeasured predictor of future Atherosclerotic Cardiovascular Disease (ASCVD). With the 25 increased use of exome sequencing in the clinical setting, there is opportunity to identify 26 patients who have a high chance of having elevated Lp(a) and are therefore at risk of ASCVD. 27 However, accurate genetic predictors of Lp(a) are challenging to design. In addition to single 28 nucleotide variants (SNVs), which are often summarized as a combined genetic risk score, 29 Lp(a) levels are significantly impacted by copy number variation in repeats of the kringle IV 30 subtype 2 domain (KIV-2), which are challenging to guantify. KIV-2 copy numbers are highly 31 variable across populations, and understanding their impact on Lp(a) levels is important to 32 creating an equitable and reliable genetic predictor of Lp(a)-driven cardiovascular risk for all 33 individuals.

34

35 **Methods:** We develop a novel method to quantify individuals' total number of KIV-2 repeats 36 from exome data, validate this quantification against measured Lp(a) levels, and then use this 37 method, combined with a SNV-based genetic risk score, to genotype an entire all-comers cohort

2

of individuals from health systems across the United States (Helix Research Network; N = 76,147) for an estimated Lp(a) level.

40

41 **Results:** Our combined genotyping strategy improved prediction of those with clinically-elevated 42 Lp(a) measurements across the genetically diverse cohort, especially for individuals not genetically similar to European reference populations, where GRS-based estimates fall short 43 44 $(r^2 = 0.04 \text{ for GRS}, r^2 = 0.34 \text{ KIV2+GRS} \text{ in non-European})$. Importantly, high combined genetic 45 risk of high Lp(a) genotypes are significantly associated with earlier onset and increased 46 incidence in ASCVD, compared to average and low combined genetic risk genotypes in a 47 retrospective analysis of atherosclerotic diagnoses derived from electronic health records 48 (EHRs). This holds in the cohort at large (CAD HRs=1.29, 1.58), in the European subcohort 49 (HRs=1.30,1.61) as well as at trending levels of significance in individuals not genetically similar 50 to Europeans (HRs=1.22,1.31). In addition, high combined genetic risk for high Lp(a) genotypes 51 are at least 2-fold enriched amongst individuals with ASCVD diagnosis despite a lack of EHR-52 based evidence of traditional risk factors for cardiovascular disease.

53

54 **Conclusions:** Our study demonstrates that genetically predicted Lp(a) levels, incorporating 55 both SNV and our novel KIV-2 repeat estimate, may be a practical method to predict clinically 56 elevated Lp(a). Supporting this, individuals with high combined genetic risk for high Lp(a) have

57 an increased risk for ASCVD, as evidenced across data from seven US-based health systems.

58 Introduction

59 Lipoprotein(a), or Lp(a), is an atherogenic lipoprotein particle comprised of two core 60 components: low-density lipoprotein (LDL) and apolipoprotein(a), the latter of which is genetically encoded by the LPA gene (Marcovina and Koschinsky 1998). Circulating Lp(a) 61 62 levels are predominantly determined by genetics, with the majority of variability in these levels 63 linked to variations at the LPA locus (Utermann et al. 1987; Kraft et al. 1996; Clarke et al. 2009; Schmidt et al. 2016; Tsimikas and Marcovina 2022). Lp(a) levels can vary up to a hundred-fold 64 among individuals, with different population subgroups exhibiting shifted distributions and 65 66 medians(Varvel et al. 2016; Tsimikas 2017; Tsimikas and Marcovina 2022; Dudum et al. 2024). 67

68 Elevated Lp(a) levels—typically cited as roughly 120 nmol/L (50 mg/dL) or above—are present 69 in 20% of the population and have been identified as a predictor of Atherosclerotic 70 Cardiovascular Disease (ASCVD), independently of established ASCVD risk factors like LDL 71 (Kamstrup et al. 2009; Emerging Risk Factors Collaboration et al. 2009; Nordestgaard et al. 72 2010; Koschinsky et al. 2024). While some studies suggest different clinical risk level thresholds 73 for primary and secondary prevention of ASCVD may be warranted, there is consensus that 74 higher levels of Lp(a) are associated with increased ASCVD risk at the population level and 75 across ethnicities, gender, baseline ASCVD status, and subpopulations such as those with Type 2 Diabetes (T2D) (Ergou et al. 2010; Varvel et al. 2016; Patel et al. 2021; Berman et al. 2024; 76 77 Wong et al. 2024). Aligned with this evidence, there are also emerging professional guidelines 78 that support incorporating Lp(a) screening strategies. Both universal, one-time Lp(a) screening 79 for adults or screening of those at intermediate or high risk via established CAD risk

3

assessments have been recommended (Grundy *et al.* 2019; Cegla *et al.* 2019; Tsimikas and
Stroes 2020; Koschinsky *et al.* 2024).

82

Lp(a) is not typically measured in the course of care, and accurate measurement of Lp(a) levels 83 across the spectrum of Lp(a) isoform sizes is difficult and a known limitation of current 84 85 laboratory tests (Wilson et al. 2019). Given the high heritability of Lp(a) levels, genetic estimation of Lp(a) has the potential to be a practical alternative to more traditional lab 86 87 measurement, especially when screening populations (Reyes-Soffer et al. 2022; Trinder et al. 88 2022). Both an SNV-based genetic risk score (GRS) and KIV-2 copy number have 89 independently been used to genetically estimate clinically-relevant Lp(a) levels (Kamstrup et al. 90 2009; Burgess et al. 2018; Trinder et al. 2020). While both axes of variation contribute to 91 circulating Lp(a) levels, due to genotyping and sequencing prerequisites for each variation type, 92 the SNV-based GRS and KIV-2 copy number variation have seldom been studied together, 93 particularly in large cohorts(Mack et al. 2017; Zekavat et al. 2018).

94

95 It has been shown that the SNV-based GRS associates with ASCVD for individuals who self-96 reported their ethnicity to be European; however, this same GRS was not evaluated in those 97 who self-reported other ethnicities, limiting the clinical utility of such estimations for Lp(a)-related 98 disease risk (Trinder et al. 2020). Recent research datasets, comprising whole genome or 99 targeted LPA locus sequencing data and measured Lp(a) levels, illustrate the potential benefits 100 of incorporating both SNV and KIV-2 copy number variations to genetically estimate 101 Lp(a)(Zekavat et al. 2018; Coassin and Kronenberg 2022). The improvements in LPA genetic 102 estimations are particularly noticeable in participants with self-reported non-European 103 ancestries, where smaller KIV-2 copy number alleles, which contribute to clinically significant 104 Lp(a) elevations, are more prevalent (Mehta et al. 2022; Tsimikas and Marcovina 2022).

105

106 We genotype a large, diverse clinicogenomic cohort derived from seven health systems across 107 the United States-the Helix Research Network (HRN)--for both LPA GRS and estimated total 108 KIV-2 CNV count. We show that, in the subset of individuals with measured Lp(a) values in their 109 medical records, using the combination of these genetic elements to predict those with Lp(a) 110 levels in the clinically-elevated range is much more accurate than using either element alone. 111 To test clinical utility of these genetic-based Lp(a) predictions across ancestries, we then use 112 GRS and the estimated number of KIV-2 repeats to establish low, average and high combined 113 genetic risk Lp(a) groups across the cohort and associate these risk groups to cardiovascular 114 phenotypes with established connections to Lp(a) levels (Clarke et al. 2009; Klarin et al. 2019; 115 Kronenberg et al. 2022).

116 Methods

117 Subjects and genetic data

118 Our study comprised 76,147 genetic samples from participants in the Helix Research Network

119 (HRN) that were sequenced and analyzed at Helix using the Exome+® assay as previously

120 described, recruited from the Healthy Nevada Project (n=40,430); myGenetics (n=23,113); and

4

121 In Our DNA SC (n=12,604) (see Supplementary Table 1) (Cirulli *et al.* 2020). The HRN studies 122 were reviewed and approved by their applicable Institutional Review Boards (IRB, projects 123 956068-12 and 21143). All participants gave their informed, written consent prior to 124 participation. All data used for research were deidentified. Demographic distributions of these 125 individuals may be found in Supplementary Tables 1-3.

126 Phenotypes

127 HRN phenotypes were processed from Epic/Clarity Electronic Health Records (EHR) data as 128 previously described and updated as of January 2024 (Cirulli et al. 2020). International 129 Classification of Diseases, Ninth and Tenth Revision, US Clinical Modification (ICD-9-CM and 130 ICD-10-CM) codes and associated dates were collected from available diagnosis tables (from 131 problem lists, medical histories, admissions data, surgical case data, account data, and 132 invoices). All datasets were transformed into the OMOP Common Data Model v5.4. Therefore, 133 diagnosis codes were mapped to standard SNOMED terms and represented by concept ids. To 134 be comprehensive in our cohort definition, we used both the source concept id and the standard 135 concept id to extract relevant diagnoses.

136

137 Coronary artery disease (CAD), peripheral artery disease (PAD), aortic stenosis (AS), Ischemic 138 Stroke (IS), and myocardial infarction (MI) were defined through review of each respective 139 disease diagnosis in the phecode X map(Shuey et al. 2023), physician input, as well as a literature search around clinical diagnosis codes (ICD-10, ICD-10-CM, ICD-9-CM, SNOMED) 140 141 given the different natures of the source datasets. We identified the first record of each included 142 ICD-10, ICD-10-CM, ICD9-CM or SNOMED term for each disease phenotype to represent the 143 first occurrence of disease for the associated individual. A complete list of diagnosis codes 144 included in each phenotype definition may be found in Appendix Table 1.

145 Clinical measurements

HDL, LDL and Lp(a) measurements were identified in the HRN as any measurement matching a
set of codes to exhaustively capture blood assays encoded in different units (see Appendix
Table 2). Each measurement was transformed into a unified set of units. When measured in
mg/dL, Lp(a) was converted to nmol/L using a conversion factor of 2.15 as established in the
literature (see for example (Khera *et al.* 2014).

151 Statistical analyses

Statistical analyses were run using the statsmodel package in Python 3.7.3. For binary 152 153 variables, logistic regression or Firth logistic regression was used; for quantitative variables, 154 linear regression was used after rank-based inverse normal transformation. For time to event 155 analyses, the lifelines package was used, using age of first diagnosis received anywhere in their 156 medical record as an end point. Cox proportional hazards were adjusted for sex, age, 157 population group, and BMI, a common cardiovascular disease risk factor available for most 158 participants (n with BMI= 101,986 [94%]). Linear models were adjusted for the exome assay 159 version and KIV-2 copy number estimate (CNE) was normalized for each exome assay subset 160 (see Supplementary Figure 3).

Genetic similarity 161

162 Genetic similarity was assigned using ADMIXTURE with the 1000 Genomes Project (1KGP) 163 population set as a reference (Alexander et al. 2009; 1000 Genomes Project Consortium et al. 164 2015). To facilitate comparisons with previous studies, and to report results in populations previously underrepresented cohorts in genetics research, we divided our cohort into European 165 166 (EUR) and non-European (non-EUR) groups as follows. For each participant, we used exome-167 wide variant calls to calculate Admixture coefficients for five continental supergroups -- AFR, 168 AMR, EAS, EUR, SAS -- derived from data unifying 26 separate populations in the Phase 3 169 data of the 1000 Genomes project. Our EUR cohort includes only individuals with EUR > 0.85 (a 170 majority of their genetic similarity assigned to the European populations; and non-EUR < 0.1), 171 and non-EUR describes individuals with a majority of their ancestry assigned to any of the other 172 population groups ('AFR', 'AMR', 'EAS', 'SAS'). A full breakdown of population assignment and 173 demographics for the full cohort, as well as the subset with Lp(a) measurements, can be found 174 in Supplementary Table 1.

175

176 This approach follows guidelines on the use of population descriptors in genetics research, 177 where the EUR group represents individuals genetically similar to the EUR reference group from 178 the 1000 Genomes project and the non-EUR group represents individuals that are not 179 genetically similar to the EUR reference group.

180 Genetic measures associated with Lp(a)

181 We calculate a genetic risk score (GRS) to predict Lp(a) levels, using genetic variants and 182 corresponding effect estimates from (Trinder et al. 2020), PGS Catalog # PGP000127).

- 183 KIV-2 normalized coverage based copy number quantification
- 184

185 Exact KIV-2 copy numbers for both alleles are challenging to determine from short-read whole exome sequencing data. However, a quantification of the total KIV-2 copy number difference 186 187 among individuals sequenced by the same assay can still be used as a numerical variable to stratify variation in KIV-2 copy number for each individual. Here we developed a method to 188 189 quantify such a difference.

190

191 For any individual, an LPA allele is expected to have one copy for each of the KIV-1 and KIV-3 192 to KIV-10 domains, but an unknown number of copies of the KIV-2 domain. On reference 193 genome hg38, the LPA gene has six copies of KIV-2 domain with identical or slightly different 194 sequences, so we masked the second to sixth KIV-2 domains; we also masked the second 195 exon of the KIV-1 domain and the first exon of the KIV-3 domain due to their similarity to KIV-2. 196 Reads extracted from LPA are re-aligned to the masked chr6 reference sequence, and the 197 coverage is counted for unmasked exons of KIV domains.

198

199 The total copy number of KIV-2, estimated through KIV-2 exon 1, is guantified as the following

200 normalized coverage of KIV-2 exon 1:

6

- 201 Use KIV-i-1 to denote the coverage of KIV-i domain exon 1,
- 202 $CNE_{KIV-2-1} = KIV 2 1/(1/8 \times \sum_{i} KIV i 1)$, where $i \in \{1, 4, 5, ..., 10\}$;
- 203 Similarly, that estimated through KIV-2 exon 2 is quantified as:
- 204 $CNE_{KIV-2-2} = KIV 2 2/(1/8 \times \sum_{i=3}^{10} KIV i 1)_{i=3}$
- 205 and the final total copy number of KIV-2 is quantified as:
- 206 CNE_{KIV-2}=1/2×(CNE_{KIV-2-1}+CNE_{KIV-2-2}).
- 207 Afterwards, this copy number of KIV-2 is normalized by exome assay version to account for
- 208 variability in region coverage, forming the final KIV-2 CNE.
- 209 Assigning genetic risk of clinically elevated Lp(a)
- 210 In the distribution of individuals with empirically measured Lp(a), we set out to determine the
- 211 GRS as well as KIV-2 CNE genetic profiles of those at the extreme ends of the spectrum, which 212 represent clinically relevant ranges. We define combined cutoffs for the GRS as well as KIV-2 213 CNE to identify individuals with a high, medium, and low genetic risk of clinically elevated Lp(a). 214 For the GRS, for high risk we choose a threshold of 120 nmol/L, as the GRS effect sizes are 215 measured in units of nmol/L, to reflect the clinically significant level. For KIV-2 CNE, as it is 216 normalized per version of our exome (see above), we choose a threshold of +/-0.8 (KIV-2 CNE 217 above or below 0.8 standard deviations from the mean) to match the proportion of individuals 218 with a measured Lp(a) above 120 nmol/L. High risk is defined as either a GRS > 120 nmol/L or 219 a KIV-2 CNE below 0.8 standard deviations from the mean. Low risk is defined as either a GRS <10nmol/L or a KIV-2 CNE above 0.8 standard deviations from the mean. All other genotype 220 221 combinations are considered average risk.
- 222

223 To extrapolate to the general population, a slightly different approach is needed, as the 224 distribution of Lp(a) measures taken due to clinical care is ascertained and therefore lopsided 225 upward relative to the expected range. Nonetheless, we continue to focus on the extremes of 226 the genetic distributions on either end. We continue using the GRS thresholds of >120 nmol/L 227 and <10 nmol/L for high and low risk and match a KIV-2 CNE cutoff to reflect this proportion in 228 the general population, resulting in a cutoff of +/- 1.5 SD, somewhat more conservative than that 229 used in analyses of the subcohort with Lp(a) measures. This ensures individuals at high and low 230 ends of genetic risk of high Lp(a) are included at a roughly similar rate and that GRS and KIV-2 231 CNE are both contributing to the combined genotypes. These high and low combined genotypes 232 reflect our best understanding of clinical risk of ASCVD, but we also evaluated a threshold 233 corresponding to 150nmol/L, to represent a significant clinical endpoint (for example, see 234 (Yeang et al. 2022). The demographic distribution of the resulting risk groups calculated using 235 either a GRS cutoff of 120 nmol/L and 150nmol/L determining the KIV-2 CNE distribution 236 cutoffs can be found in Supplementary Table 3.

237 Results

- 238 Lp(a) is seldom measured in clinical practice
- 239

7

240 Within an all-comers cohort recruited from three health systems in the Helix Research Network 241 (HRN, n=76,147), we identify only 1584 (2.0%) individuals with 1777 clinically ascertained Lp(a) 242 measurements (for a full breakdown of cohort demographics, see Supplementary Table 1). In 243 contrast, 99% of individuals across this cohort have an LDL measurement. As these Lp(a) 244 measurements were taken during routine care in response to a clinical observation, we expect 245 them to be non-representative of the total population (Varvel et al. 2016; Dudum et al. 2024). 246 Indeed, the mean Lp(a) measured in the cohort is 50 nmol/L, slightly below the upper threshold 247 for normal (<75 nmol/L) and higher than the expected population mean (28-45 nmol/L) 248 (Langsted et al. 2014; Patel et al. 2021). This cohort also has a slightly elevated LDL when 249 measured (mean 101.4 mg/dL; for full comparison see Supplementary Figure 4).

- 250 SNV and KIV-2-based genetic predictor performance in those with Lp(a) levels
- 251

252 To facilitate comparisons with previous studies, and to report results in populations previously 253 underrepresented cohorts in genetics research, we divided our cohort into European (EUR) and 254 non-European (non-EUR) groups (see Methods). As expected, a previously-validated genetic 255 risk score (GRS), which outputs a genetically predicted Lp(a) level based on SNVs in LPA, is 256 associated with Lp(a) levels in EUR individuals in our cohort (n=1346) with an r² of 0.4 (see Supplemental Figure 1). However, the r² in non-EUR individuals (n=238) is 0.04, indicating little 257 predictive value of the GRS for Lp(a) levels in non-EURs. In parallel, KIV-2 copy number 258 estimation (CNE) is anticorrelated with Lp(a) levels in both subsets, with an r² of 0.32 and 0.29 259 for EUR and non-EUR cohorts, respectively (see Supplemental Figure 2). This negative 260 261 correlation is expected as a lower KIV-2 CNE implies a smaller total molecule size, which eases 262 export of the molecule, increasing measured blood levels of Lp(a) (Reyes-Soffer et al. 2022). Accordingly, a linear model combining both genetic predictors to genetically estimate Lp(a) 263 improves performance, with an r^2 of 0.49 for EUR individuals (p<2.2e-16 for both variables) and 264 265 0.34 for non-EURs (p<2.2e-16 for KIV-2 CNE; p=5.5e-6 for GRS) in the dataset; this model 266 performs better than either alone.

267

As a performance metric, the correlation coefficient measures the ability to predict the specific 268 269 Lp(a) values in a patient population. However, the key clinical outcome for population-wide 270 genetic screening is whether an individual is expected to have an Lp(a) level high enough to be 271 associated with excess risk of future cardiovascular morbidity (Grundy et al. 2019; Kronenberg 272 et al. 2022). Accordingly, we calculate an additional performance metric to determine if KIV-2 273 CNE and GRS genotype groups can be established for predicting clinically relevant Lp(a) 274 elevations (>120 nmol/L). We identify individuals with a high GRS or a low KIV-2 CNE by 275 extrapolating from the distribution for individuals with a clinically elevated Lp(a) (see Methods). 276 In the subset of individuals with low KIV-2 CNE (approximately the lower 20% of the 277 distribution), 70% of these individuals have a clinically elevated Lp(a), compared to only 17% of 278 people without this genetic risk. Likewise for individuals with high GRS (above 120 nmol/L 279 predicted), 80% have a clinically elevated Lp(a), compared to only 16% without (Figure 1, Chi 280 squared p-value < 2.2e-16). The GRS performance differs significantly by population; 88% of 281 EUR individuals with a high GRS have an elevated Lp(a), compared to only 43% of non-EUR 282 individuals. When unifying across the presence of either genetic risk, we find 89% of individuals

with either a high GRS or a low KIV-2 CNE have a clinically elevated Lp(a), compared to only 9.8% of individuals with neither genetic risk predictor. This combined model performed similarly well for individuals of both the EUR and non-EUR cohorts, in stark contrast to the ancestrybiased performance of the GRS.

287



288

289 Figure 1: GRS and KIV-2 each contribute independently to predicting Lp(a) levels.

A) Schematic representation of bioinformatic process for KIV-2 copy number estimate (CNE) and calculation of the *LPA* GRS score. B) Proportion of individuals in each category with an Lp(a) > 120nmol/L, divided by membership in either EUR ('European') or non-EUR ('Non Eur') cohort. From left to right, 'high GRS' is a GRS > 120 nmol/L (as the GRS is in units of predicted Lp(a)); 'low KIV-2' denotes a normalized KIV-2 less than 0.8 standard deviations from the mean; and 'high GRS or low KIV-2' indicates that a patient was included for either reason. Although some individuals with high GRS may have a non-risk KIV-2, and vice versa, 'low PRS or high KIV-2' are individuals with neither genetic risk factor.

297

298 Combined genetic risk for predicting clinically-relevant Lp(a) levels

Guided by this data, we developed a population-level, ancestry-agnostic genotyping approach for categorizing genetic Lp(a) risk leveraging both our KIV-2 CNE and the *LPA* GRS. Specifically, we assign individuals to have a combined genetic risk for a high Lp(a) ("high combined genetic risk") if they have either a GRS >120 nmol/L or a KIV-2 CNE below 1.5 standard deviations from the mean (n=14,355, or 18% of the participants). The remaining

9

individuals are considered to have a low combined genetic risk for a high Lp(a) ("low combined genetic risk") if they have a GRS < 10 nmol/L or a KIV-2 CNE above 1.5 standard deviations from the mean (n=8,659). The remaining individuals harbor genetic profiles indicative of average Lp(a) levels (n=53,133). Notably, the average LDL for individuals with recorded lab values is consistent between these genetic groups, ranging between 104-107 (Supplementary Figure 4).

Combined genetic risk, predicting clinically-elevated Lp(a), is associated with increased
 ASCVD diagnoses in both EUR and non-EUR individuals

312 Next, we investigate association of our combined genetic risk groups with cardiovascular 313 disease diagnoses associated with clinically-elevated Lp(a) including coronary artery disease 314 (CAD), peripheral artery disease (PAD), myocardial infarction (MI), aortic stenosis (AS), 315 ischemic stroke (IS), as well as the five-point Major Adverse Cardiovascular Event (MACE) 316 index. For each phenotype, we compare the rate and age of onset of these diagnoses between 317 the high and average and high and low combined genetic risk groups using a Cox regression 318 controlling for sex, age, population group, and BMI to calculate a proportional hazard ratio (HR) 319 for each comparison. We find significant proportional hazards for CAD, PAD, MI, AS and MACE, 320 with an increase in the magnitude of these differences when comparing the high combined 321 genetic risk group to the average combined genetic risk group (e.g. CAD HR=1.29 [1.22-1.38], 322 p= 2.01e-16; PAD HR=1.34 [1.08-1.66], p = 0.0015) and low combined genetic risk group (CAD 323 HR= 1.58[1.43-1.75], p=4.89 e-18; PAD HR= 2.05 [1.39-3.03], p=6.8e-5) (See Figure 2 and 324 Appendix 2 for all pairwise combinations). IS was only moderately enriched in the high 325 combined genetic risk group compared to the low combined genetic risk group (HR = 1.19[1.02-326 1.41], p = 0.03).

327

328 Next, we re-test for association in EUR (n=61,406) and non-EUR (n=14,741) cohorts 329 separately. As expected, given sample size enrichment (81% of cohort) and established 330 performance of GRS against similar outcomes, all comparisons remain significant in the EUR 331 subset(Figure 3B, Appendix 2). Despite the substantially smaller sample sizes of the high 332 (n=3,349) and low (n=1,798) combined genetic risk groups for non-EUR cohort, we observe 333 similar stepwise increases in hazard ratio confidence intervals for the suite of phenotypes with 334 significant HR differences in the cohort at large (Figure 3B, Appendix 2). In particular, 335 differences in diagnoses trends for CAD between the high and average combined genetic risk 336 groups and high and low combined genetic risk groups trend towards significance 337 (HR=1.22[1.0-1.48], p=0.04; HR=1.31[0.98-1.76], p=0.06). The exception was AS in the high vs. 338 the low combined genetic risk group for non-EUR, where low power was an issue (36% power 339 to detect the effect size seen in the EUR group in the non-EUR group). Nonetheless, without the 340 use of a clinical Lp(a) measurement, these genetically predicted Lp(a) risk groups identify 341 individuals with an increased incidence of future cardiovascular morbidity.

10



342

Figure 2. Elevated combined genetic risk of a high Lp(a) is associated with increased phenotype incidence after adjusting for age, sex, BMI and population of origin. A) the cumulative fraction of individuals with coronary artery disease, divided by their Lp(a) combined genetic risk group (high, average, or low). B) The Cox proportional hazard ratio and 95% confidence intervals for high versus average or high versus low combined genetic risk of high Lp(a) groups across statistical significant phenotypes in the unified cohort, as well as these estimations in subcohorts separated by genetic similarity (EUR or non-EUR cohorts).

350 Predicted Lp(a) and incidence of ASCVD in individuals with otherwise low risk

351 In addition to increasing ASCVD risk independently of other risk factors like LDL, Lp(a) is also 352 suspected to contribute to the incidence of premature or otherwise unexpected ASCVD 353 (Verbeek et al. 2018). To measure the latent contribution of a high combined genetic risk of high 354 Lp(a) to unexpected ASCVD, we subsetted our cohort to individuals with a lower risk of 355 cardiovascular disease using key risk factors available from EHR records. We included 356 individuals with either no LDL measurement or a low clinically-ascertained measurement (<100 357 mg/dL, but >50mg/dL, to exclude people with other possible lipid disorders), low age (<55), and 358 most recent BMI < 30 (Zhou et al. 2021; Wong et al. 2022). As expected, this subset has a 359 substantially lowered incidence of CAD (Figure 3). Next, we compared the percentage of 360 individuals in each combined genetic risk category with an early ASCVD diagnosis (age <55). 361 The mean age in each risk category in this analysis was similar (41.4, 41.5, and 41.4 years 362 across high, medium, and low risk groups; see Supplemental Figure 5) so comparing incidence 363 across groups is not biased by age of onset or followup time. We find that 1.2-1.6% of 364 individuals with a high combined genetic risk of a high Lp(a) in this low traditional risk cohort 365 harbor a diagnosis of CAD or MI, compared to 0.6-0.7% of low traditional risk individuals with a low combined genetic risk of high Lp(a) (Figure 3). 366

367

11

368 Another way to summarize this contribution to excess risk is to calculate the proportion of 369 individuals in high combined genetic risk of high Lp(a) receiving premature diagnoses compared 370 to the overall representation of the group in the population. Using CAD as an example, we find 371 that while individuals with a high combined genetic risk of high Lp(a) are 17% of the low risk 372 population, they comprise 27% of low canonical risk individuals who are nonetheless diagnosed 373 with CAD (binomial test, p-value = 0.014). Across ASCVD diagnoses in this low risk population, 374 there is 2-fold enrichment in those with high combined genetic risk of high Lp(a) compared to 375 those with low combined genetic risk of Lp(a) (Figure 3). While these enrichments may not 376 account for the majority of cardiovascular morbidity, elevated Lp(a) represents an unobserved 377 determinant of risk, and may explain nearly a third of individuals diagnosed with disease who 378 lack other canonical risk factors.

379



_ _ _

380 genetic risk of high Lp(a)
 381 Figure 3: Proportion of individuals at low canonical risk with disease diagnoses. The proportion of individuals in each
 382 Lp(a) genetic risk group receiving a diagnosis. These individuals are all restricted to age <55, BMI < 30, and either no
 383 LDL measurement or a low measurement, to include only individuals with no canonical risk factors for cardiovascular

383 LDL measuremen 384 disease.

385 Discussion

386 Genetic prediction of Lp(a) levels presents significant challenges as well as significant potential 387 for precision medicine and prevention of future risk of Atherosclerotic Cardiovascular Disease 388 (ASCVD). In this work, we develop a practical method to estimate the number of copies of KIV-2 389 (KIV-2 CNE) from exome sequencing in the Helix Research Network, an all-comers cohort 390 collected from multiple health system sites across the United States. While genetic risk scores 391 (GRS) applied in the clinic are known to perform poorly in understudied and underrepresented 392 genetic groups, KIV-2 CNE is a population-agnostic genetic risk predictor (Privé et al. 2022; 393 Kullo et al. 2022). KIV-2 CNE performed well to predict Lp(a) in both the Europrean (EUR) and 394 non- European (non-EUR) subsets of our cohort with Lp(a) measurements (Figure 1). 395 Independent of genetic similarity group, individuals with a low KIV-2 CNE are 5-fold more likely

12

to present with elevated Lp(a) levels (80% vs 16%, Chi squared p-value < 2.2e-16). This
 demonstrates the opportunity to develop a scalable genetic risk predictor and with equitable
 performance, which we test across a diverse health system cohort.

399

400 We use KIV-2 CNE in combination with a GRS to develop a combined genetic risk predictor of 401 high Lp(a) and genotype a cohort of 76,417 individuals for this genetic risk. This exome-based 402 categorization of combined genetic risk of high Lp(a) is associated with increased incidence and 403 earlier onset of coronary artery disease, myocardial infarction, heart failure, and other 404 phenotypes associated with ASCVD with strong statistical significance in both the cohort at 405 large, the EUR subset, and with trending significance and similar direction of effects in the non-406 EUR subcohort (Figure 2). Encouragingly, the hazard ratio estimate for our combined high 407 genetic risk group compared to the low risk group for coronary artery disease (HR=1.6, whole 408 cohort; p-value = 2e-19) is similar to the established hazard ratios from association studies 409 based on actual measures of clinically-elevated Lp(a), confirming that this genetic estimate is a 410 useful clinical instrument for predicting elevated Lp(a) levels (Finneran et al. 2021).

411

412 Lp(a) has been shown to predict cardiovascular morbidity risk independently of leading risk 413 factors, such as LDL, age, and BMI, as well as in individuals who develop ASCVD without any 414 of these canonical risk factors. Amongst patients at low canonical risk in our cohort, there is a 2-415 fold enrichment of individuals with a high combined genetic risk of high Lp(a) compared to low 416 combined genetic risk individuals, and this high risk group accounts for 27% of unexpected 417 cases of coronary artery disease (Figure 3). This suggests that our genetic measure may help 418 identify additional individuals with elevated ASCVD risk not identified based on standard risk 419 scoring measures.

420

421 This study does not exhaustively look at all possible genetic variation in Lp(a) with an impact on 422 Lp(a) levels; recent work has shown that SNVs in the KIV-2 repeat itself are impactful, although 423 likely less impactful on Lp(a) than population-specific variation in the abundance of KIV-2 (Di 424 Maio et al. 2020; Schachtl-Riess et al. 2021; Behera et al. 2023). Future work incorporating 425 SNVs, particularly in the KIV-2 region, as well as tailoring the distribution thresholds for high and 426 low KIV-2 copy number estimates may improve the precision of these genetic estimations. One 427 of the major limitations of studies that rely on retrospective analyses of EHR is the lack of 428 detailed phenotyping over a longitudinal timespan and inherent selection bias in building a 429 dataset from participants actively engaging with the healthcare system. Although EHRs are very 430 comprehensive, many data points are not recorded with the desired frequency or detail, and 431 coding patterns vary by both physician and health system and will be biased by the overall 432 engagement of each participant with the health system, making it challenging to 433 comprehensively apply known ASCVD risk estimates (D'Agostino et al. 2008). Despite these 434 limitations, using EHR data for phenotyping provides an opportunity to evaluate genetic 435 associations with health outcomes at a population level, creating evidence to support more 436 detailed clinical follow up projects. For example, based on this retrospective analysis, we 437 believe a prospective analysis validating this combined genetic estimation of high Lp(a) against clinically-measured Lp(a) levels more broadly across populations is warranted based on these 438 439 preliminary findings.

440

441 Therapy options for patients with elevated Lp(a) are limited. Current available lipid lowering 442 drugs do not provide targeted Lp(a) lowering. PCSK9 monoclonal antibody inhibitors modestly 443 decrease Lp(a) levels(Burgess et al. 2018; O'Donoghue et al. 2019; Lamina et al. 2019; Bittner 444 et al. 2020). In patients with clinical ASCVD and recurrent events, if Lp(a) is elevated, apheresis 445 can be considered; however, this is a cumbersome and undesirable option for most patients 446 (Leebmann et al. 2013; Pokrovsky et al. 2016). Multiple novel nucleic acid therapies that lower 447 Lp(a) are currently being studied in phase III clinical outcomes trials (Tsimikas et al. 2020; 448 O'Donoghue et al. 2022). Pelacarsen, an antisense oligonucleotide, and olezarsen, a small 449 interfering RNA (siRNA), have been found to safely reduce Lp(a) by 40-80% depending on the 450 dose and frequency of injections. The HORIZON and OCEAN(a) trials will determine if these 451 medications reduce cardiovascular events in patients with a history of clinical ASCVD; these 452 results are expected as early as 2025. Additionally, the ACCLAIM-Lp(a) trial will investigate 453 lepodisiran, another siRNA that reduces Lp(a), in a phase III clinical outcomes trial for both 454 primary and secondary prevention patients. Currently, Lp(a) measurement is used mostly for 455 ASCVD risk stratification, but if these pharmaceutical options prove to reduce cardiovascular 456 events, there will be an even greater interest in identifying patients with elevated Lp(a) for 457 prevention.

458

459 Lp(a) is rarely measured as part of clinical practice: in our clinical cohort, only 1.4% of patients 460 had a documented Lp(a) measurement taken. In contrast, every one of them has been 461 sequenced. As sequencing becomes an established part of routine care, the impact of genetic 462 data on treatment and preventative medicine will be determined by the efficacy and fairness of 463 genomic predictors of future morbidity. Accordingly, we develop a predictor which performs 464 similarly to the value of the actual lab measurement in patients where it has been ascertained, 465 and which is highly sensitive regardless of ancestry and population of origin. This crosspopulation performance is crucial to the fair and equitable development of genetic medicine, and 466 467 is rarely achieved in the development of polygenic predictors (Wang et al. 2020; Privé et al. 2022; Kullo et al. 2022; Aw et al. 2024). This predictor enables us to identify patients at 468 469 significantly higher risk of future cardiovascular disease, which can both compound traditional 470 risk as well as identify at risk individuals who present without canonical risk factors. In short, this 471 genomic-based predictor for high Lp(a), which may be calculated for any patient regardless of 472 current diagnoses, family history, or other measured risk factors, is both a fair future predictor of 473 cardiovascular morbidity and demonstrates that 27% of unexplained coronary artery disease 474 may be attributed to a combined genetic risk of elevated Lp(a). This work advances the 475 evidence base supporting Lp(a) estimation as a potential equitable baseline health measure 476 from genetic data, especially as exome sequencing for disease risk estimation and prevention 477 becomes more common in medicine.

- 478
- 479 **Declaration of Interests**
- 480 KMSB, ETC, AB, NT, WL, SL, BK, HD, and NLW are all employees of Helix.
- 481
- 482 Acknowledgments

14

- 483 We acknowledge the entire Helix bioinformatics and lab teams for their contributions to the
- 484 production of exome sequencing pipeline as well as the research administration team for
- 485 coordinating the project. We thank all of the participants of the Helix Research Network.
- 486

487 Funding

- 488 Funding was provided to the Desert Research Institute by the Renown Institute for Health
- 489 Innovation and the Renown Health Foundation. Funding was provided to DRI by the Nevada
- 490 Governor's Office of Economic Development. Funding was provided to the myGenetics program
- 491 by HealthPartners.
- 492

493 Ethics Declaration

- 494 The Helix cohorts were reviewed by Salus IRB (Reliance on Salus for all sites) and approved
- 495 (approval number 21143), the WCG IRB (Western Institutional Review Board, WIRB-
- 496 Copernicus Group) and approved (approval number 20224919), the MUSC Institutional Review
- 497 Board for Human Research and approved (approval number Pro00129083), and the University
- 498 of Nevada, Reno Institutional Review Board and approved (approval number 7701703417). All
- 499 participants gave their informed, written consent before participation. All data used for research500 were de-identified.
- 501

502 References

503

- 504 1000 Genomes Project Consortium, A. Auton, L. D. Brooks, R. M. Durbin, E. P. Garrison, et al.,
- 505 2015 A global reference for human genetic variation. Nature 526: 68–74.
- 506 Alexander D. H., J. Novembre, and K. Lange, 2009 Fast model-based estimation of ancestry in
- 507 unrelated individuals. Genome Res. 19: 1655–1664.
- 508 Aw A. J., J. McRae, E. Rahmani, and Y. S. Song, 2024 Highly parameterized polygenic scores
- 509 tend to overfit to population stratification via random effects. bioRxiv.
- 510 https://doi.org/10.1101/2024.01.27.577589

15

511	Behera S., J. R. Belyeu, X. Chen, L. F. Paulin, N. Q. H. Nguyen, et al., 2023 Identification of
512	allele-specific KIV-2 repeats and impact on Lp(a) measurements for cardiovascular disease
513	risk. bioRxivorg. https://doi.org/10.1101/2023.04.24.538128

- 514 Berman A. N., D. W. Biery, S. A. Besser, A. Singh, A. Shiyovich, et al., 2024 Lipoprotein(a) and
- 515 major adverse cardiovascular events in patients with or without baseline atherosclerotic
- 516 cardiovascular disease. J. Am. Coll. Cardiol. 83: 873–886.
- 517 Bittner V. A., M. Szarek, P. E. Aylward, D. L. Bhatt, R. Diaz, *et al.*, 2020 Effect of alirocumab on
- 518 lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J. Am. Coll. Cardiol.
- 519 75: 133–144.
- 520 Burgess S., B. A. Ference, J. R. Staley, D. F. Freitag, A. M. Mason, et al., 2018 Association of
- 521 LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-
- 522 Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol 3: 619–627.
- 523 Cegla J., R. D. G. Neely, M. France, G. Ferns, C. D. Byrne, *et al.*, 2019 HEART UK consensus 524 statement on Lipoprotein(a): A call to action. Atherosclerosis 291: 62–70.
- 525 Cirulli E. T., S. White, R. W. Read, G. Elhanan, W. J. Metcalf, *et al.*, 2020 Genome-wide rare
 526 variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts. Nat.
 527 Commun. 11: 542.
- 528 Clarke R., J. F. Peden, J. C. Hopewell, T. Kyriakou, A. Goel, *et al.*, 2009 Genetic variants
 529 associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361: 2518–
 530 2528.
- Coassin S., and F. Kronenberg, 2022 Lipoprotein(a) beyond the kringle IV repeat polymorphism:
 The complexity of genetic variation in the LPA gene. Atherosclerosis 349: 17–35.

16

- D'Agostino R. B. Sr, R. S. Vasan, M. J. Pencina, P. A. Wolf, M. Cobain, *et al.*, 2008 General
 cardiovascular risk profile for use in primary care: the Framingham Heart Study: The
- 535 Framingham heart study. Circulation 117: 743–753.
- 536 Di Maio S., R. Grüneis, G. Streiter, C. Lamina, M. Maglione, et al., 2020 Investigation of a
- 537 nonsense mutation located in the complex KIV-2 copy number variation region of
- 538 apolipoprotein(a) in 10,910 individuals. Genome Med. 12: 74.
- 539 Dudum R., Q. Huang, X. S. Yan, M. A. Fonseca, P. Jose, et al., 2024 Lipoprotein(a) levels in
- 540 disaggregated racial and ethnic subgroups across atherosclerotic cardiovascular disease
- 541 risk levels. JACC Adv. 3: 100940.
- 542 Emerging Risk Factors Collaboration, S. Erqou, S. Kaptoge, P. L. Perry, E. Di Angelantonio, et
- *al.*, 2009 Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and
 nonvascular mortality. JAMA 302: 412–423.
- 545 Erqou S., A. Thompson, E. Di Angelantonio, D. Saleheen, S. Kaptoge, et al., 2010
- 546 Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies 547 involving 58,000 participants. J. Am. Coll. Cardiol. 55: 2160–2167.
- 548 Finneran P., A. Pampana, S. A. Khetarpal, M. Trinder, A. P. Patel, *et al.*, 2021 Lipoprotein(a)

and Coronary Artery Disease Risk Without a Family History of Heart Disease. J Am HeartAssoc 10: e017470.

- 551 Grundy S. M., N. J. Stone, A. L. Bailey, C. Beam, K. K. Birtcher, et al., 2019 2018
- 552 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the
- 553 management of blood cholesterol: Executive summary: A report of the American college of
- 554 cardiology/American heart association task force on clinical practice guidelines. J. Am. Coll.
- 555 Cardiol. 73: 3168–3209.

17

556	Kamstrup P. R., A. Tybjaerg-Hansen, R. Steffensen, and B. G. Nordestgaard, 2009 Genetically
557	elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301: 2331–2339.

- 558 Khera A. V., B. M. Everett, M. P. Caulfield, F. M. Hantash, J. Wohlgemuth, et al., 2014
- 559 Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis
- 560 from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention
- 561 Trial Evaluating Rosuvastatin). Circulation 129: 635–642.
- 562 Klarin D., J. Lynch, K. Aragam, M. Chaffin, T. L. Assimes, et al., 2019 Genome-wide association
- study of peripheral artery disease in the Million Veteran Program. Nat. Med. 25: 1274–
 1279.
- 565 Koschinsky M. L., A. Bajaj, M. B. Boffa, D. L. Dixon, K. C. Ferdinand, *et al.*, 2024 A focused
- update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J.
 Clin. Lipidol. 18: e308–e319.
- 568 Kraft H. G., A. Lingenhel, R. W. Pang, R. Delport, M. Trommsdorff, *et al.*, 1996 Frequency
- 569 distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a)
- 570 levels in Caucasian, Asian, and African populations: the distribution of null alleles is non-
- 571 random. Eur. J. Hum. Genet. 4: 74–87.
- 572 Kronenberg F., S. Mora, E. S. G. Stroes, B. A. Ference, B. J. Arsenault, et al., 2022
- 573 Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European
- 574 Atherosclerosis Society consensus statement. Eur. Heart J. 43: 3925–3946.
- 575 Kullo I. J., C. M. Lewis, M. Inouye, A. R. Martin, S. Ripatti, *et al.*, 2022 Polygenic scores in
 576 biomedical research. Nat. Rev. Genet. 23: 524–532.
- 577 Lamina C., F. Kronenberg, and Lp(a)-GWAS-Consortium, 2019 Estimation of the required
- 578 lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease

- 580 JAMA Cardiol. 4: 575–579.
- 581 Langsted A., P. R. Kamstrup, and B. G. Nordestgaard, 2014 Lipoprotein(a): fasting and
- 582 nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis 234: 95–101.
- 583 Leebmann J., E. Roeseler, U. Julius, F. Heigl, R. Spitthoever, et al., 2013 Lipoprotein apheresis
- 584 in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-
- 585 hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational
- 586 multicenter study: Prospective observational multicenter study. Circulation 128: 2567–2576.
- 587 Mack S., S. Coassin, R. Rueedi, N. A. Yousri, I. Seppälä, et al., 2017 A genome-wide
- 588 association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a)
- 589 isoforms. J. Lipid Res. 58: 1834–1844.
- Marcovina S. M., and M. L. Koschinsky, 1998 Lipoprotein(a) as a risk factor for coronary artery
 disease. Am. J. Cardiol. 82: 57U–66U; discussion 86U.
- Mehta A., V. Jain, A. Saeed, J. J. Saseen, M. Gulati, *et al.*, 2022 Lipoprotein(a) and ethnicities.
 Atherosclerosis 349: 42–52.
- Nordestgaard B. G., M. J. Chapman, K. Ray, J. Borén, F. Andreotti, *et al.*, 2010 Lipoprotein(a)
 as a cardiovascular risk factor: current status. Eur. Heart J. 31: 2844–2853.
- 596 O'Donoghue M. L., S. Fazio, R. P. Giugliano, E. S. G. Stroes, E. Kanevsky, et al., 2019
- 597 Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 139: 1483–1492.
- 598 O'Donoghue M. L., J. A. G López, B. Knusel, B. Gencer, H. Wang, et al., 2022 Study design
- and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-
- 600 DOSE finding study (OCEAN(a)-DOSE). Am. Heart J. 251: 61–69.

- 601 Patel A. P., M. Wang (汪敏先), J. P. Pirruccello, P. T. Ellinor, K. Ng, et al., 2021 Lp(a)
- 602 (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New
- 603 Insights From a Large National Biobank. Arterioscler. Thromb. Vasc. Biol. 41: 465–474.
- Pokrovsky S. N., O. I. Afanasieva, and M. V. Ezhov, 2016 Lipoprotein(a) apheresis. Curr. Opin.
 Lipidol. 27: 351–358.
- 606 Privé F., H. Aschard, S. Carmi, L. Folkersen, C. Hoggart, et al., 2022 Portability of 245
- 607 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from
- the same cohort. Am. J. Hum. Genet. 109: 12–23.
- 609 Reyes-Soffer G., H. N. Ginsberg, L. Berglund, P. B. Duell, S. P. Heffron, et al., 2022
- 610 Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for
- 611 Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart
- 612 Association. Arterioscler. Thromb. Vasc. Biol. 42: e48–e60.
- 613 Schachtl-Riess J. F., A. Kheirkhah, R. Grüneis, S. Di Maio, S. Schoenherr, et al., 2021 Frequent
- 614 LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary
- 615 Artery Disease. J. Am. Coll. Cardiol. 78: 437–449.
- Schmidt K., A. Noureen, F. Kronenberg, and G. Utermann, 2016 Structure, function, and
 genetics of lipoprotein (a). J. Lipid Res. 57: 1339–1359.
- Shuey M. M., W. W. Stead, I. Aka, A. L. Barnado, J. A. Bastarache, *et al.*, 2023 Next-generation
 phenotyping: Introducing PhecodeX for enhanced discovery research in medical
 phenomics. medRxiv.
- Trinder M., M. M. Uddin, P. Finneran, K. G. Aragam, and P. Natarajan, 2020 Clinical Utility of
 Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic

- 623 Cardiovascular Disease. JAMA Cardiol 6: 1–9.
- 624 Trinder M., K. Paruchuri, S. Haidermota, R. Bernardo, S. M. Zekavat, et al., 2022 Repeat
- 625 measures of lipoprotein(a) molar concentration and cardiovascular risk. J. Am. Coll.
- 626 Cardiol. 79: 617–628.
- Tsimikas S., 2017 A test in context: Lipoprotein(a): Diagnosis, prognosis, controversies, and
 emerging therapies. J. Am. Coll. Cardiol. 69: 692–711.
- 629 Tsimikas S., E. Karwatowska-Prokopczuk, I. Gouni-Berthold, J.-C. Tardif, S. J. Baum, et al.,
- 630 2020 Lipoprotein(a) reduction in persons with cardiovascular disease. N. Engl. J. Med. 382:
- 631 244–255.
- Tsimikas S., and E. S. G. Stroes, 2020 The dedicated "Lp(a) clinic": A concept whose time has
 arrived? Atherosclerosis 300: 1–9.
- Tsimikas S., and S. M. Marcovina, 2022 Ancestry, lipoprotein(a), and cardiovascular risk
 thresholds: JACC review topic of the week. J. Am. Coll. Cardiol. 80: 934–946.
- Utermann G., H. J. Menzel, H. G. Kraft, H. C. Duba, H. G. Kemmler, *et al.*, 1987 Lp(a)
- 637 glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in
 638 plasma. J. Clin. Invest. 80: 458–465.
- 639 Varvel S., J. P. McConnell, and S. Tsimikas, 2016 Prevalence of elevated LP(a) mass levels
- and patient thresholds in 532 359 patients in the United States. Arterioscler. Thromb. Vasc.
 Biol. 36: 2239–2245.
- 642 Verbeek R., R. M. Hoogeveen, A. Langsted, L. C. A. Stiekema, S. L. Verweij, et al., 2018
- 643 Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-
- 644 density lipoprotein cholesterol levels in a primary prevention setting. Eur. Heart J. 39:

21

645 2589–2596.

- 646 Wang Y., J. Guo, G. Ni, J. Yang, P. M. Visscher, *et al.*, 2020 Theoretical and empirical
- 647 quantification of the accuracy of polygenic scores in ancestry divergent populations. Nat.
- 648 Commun. 11: 3865.
- 649 Wilson D. P., T. A. Jacobson, P. H. Jones, M. L. Koschinsky, C. J. McNeal, et al., 2019 Use of
- 650 Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement
- from the National Lipid Association. J. Clin. Lipidol. 13: 374–392.
- Wong N. D., M. J. Budoff, K. Ferdinand, I. M. Graham, E. D. Michos, et al., 2022 Atherosclerotic
- 653 cardiovascular disease risk assessment: An American Society for Preventive Cardiology
 654 clinical practice statement. Am. J. Prev. Cardiol. 10: 100335.
- Wong N. D., W. Fan, X. Hu, C. Ballantyne, R. C. Hoodgeveen, *et al.*, 2024 Lipoprotein(a) and
 long-term cardiovascular risk in a multi-ethnic pooled prospective cohort. J. Am. Coll.
 Cardiol. 83: 1511–1525.
- Yeang C., E. Karwatowska-Prokopczuk, F. Su, B. Dinh, S. Xia, *et al.*, 2022 Effect of pelacarsen
 on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J. Am. Coll.
 Cardiol. 79: 1035–1046.
- Zekavat S. M., S. Ruotsalainen, R. E. Handsaker, M. Alver, J. Bloom, *et al.*, 2018 Deep
 coverage whole genome sequences and plasma lipoprotein(a) in individuals of European
 and African ancestries. Nat. Commun. 9: 2606.
- Zhou Z., J. Macpherson, S. R. Gray, J. M. R. Gill, P. Welsh, *et al.*, 2021 Are people with
 metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK
- 666 Biobank participants. Diabetologia 64: 1963–1972.